$NVAX Cashflow Statement | Understand Stock

$NVAX

$10.02 +$0.62 (6.54%) Live

$NVAX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities:
Net income (loss)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization
Gain on sale of assets
Right-of-use assets expensed
Gain on disposition of Novavax CZ assets
Right-of-use assets expensed, net of credits received
Stock-based compensation
Provision for excess and obsolete inventory
Impairment of assets held for sale
Impairment of other long-lived assets
Loss on debt extinguishment
Other items, net
Changes in operating assets and liabilities:
Inventory
Accounts receivable, prepaid expenses, and other assets
Accounts payable, accrued expenses, and other liabilities
Deferred revenue

Net cash used in operating activities
Investing Activities:
Capital expenditures
Internal-use software
Acquisition of Novavax CZ, net of cash acquired
Proceeds from sale of assets
Proceeds from Assets held for sale
Proceeds from disposition of Novavax CZ assets
Purchases of marketable securities
Proceeds from maturities of marketable securities
Net cash used in investing activities

Financing Activities:
Net proceeds from sale of preferred stock
Net proceeds from sales of common stock
Proceeds on the issuance of Convertible Senior Notes due 2031, net of issuance costs
Payments of costs related to issuance of 2027 Convertible notes
Proceeds from the exercise of stock-based awards, net of tax withholding
Repayment of 2023 Convertible notes
Finance lease payments
Net cash provided by financing activities

Effect of exchange rate on cash, cash equivalents, and restricted cash
Net decrease in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year
Supplemental disclosure of non-cash activities:
Issuance of Convertible Senior Notes due 2031 in exchange for Convertible Senior Notes due 2027
Sale of common stock under the Sales Agreement not settled at year-end
Capital expenditures included in accounts payable and accrued expenses
Right-of-use assets from new lease agreements, net of tenant improvement allowance on facility leases
Supplemental disclosure of cash flow information:
Cash interest payments, net of amounts capitalized
Cash paid for income taxes, net of refunds received

Comments